T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
馬薩諸塞州列剋星敦，2024年4月24日（GLOBE NEWSWIRE）——敗血症致病原體和抗生素耐藥基因快速檢測領域的領導者T2 Biosystems, Inc.（納斯達克股票代碼：TTOO）今天宣佈，將在2024年5月6日星期一收盤後公佈2024年第一季度的財務業績和業務最新情況。公司管理層將從美國東部時間下午 4:30 開始舉行相應的電話會議。
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 160751, approximately ten to five minutes prior to the start time.
有興趣收聽電話會議的投資者可以通過訪問該活動的直播和存檔網絡直播來收聽電話會議 www.t2biosystems.com，在 “活動和演示” 部分的 “投資者” 頁面上。要收聽電話會議，請在開始時間前大約十到五分鐘撥打 1-888-506-0062（美國/加拿大）或 1-973-528-0011（國際），密碼爲160751。
About T2 Biosystems
關於 T2 生物系統
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. For more information, please visit www.t2biosystems.com.
T2 Biosystems是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，致力於通過幫助臨床醫生比以往任何時候都更快地有效治療患者來改善患者護理和降低護理成本。T2 Biosystems 的產品包括 T2Dx 儀器，T2Bertia 小組，T2Candida 面板，T2Restance 面板和 T2Biothreat Panel，由專有的 T2 磁共振 (T2MR) 提供動力) 技術。T2 Biosystems 擁有活躍的未來產品線，包括美國的 T2Resistance 小組、 耳念珠菌 測試，以及 T2Lyme 小組。欲了解更多信息，請訪問 www.t2biosystems.com。
投資者聯繫人：
菲利普·特里普泰勒，吉爾馬丁集團
ir@T2Biosystems.com415-937-5406
Source: T2 Biosystems, Inc.
來源：T2 Biosystems, Inc.